



Bipolar vaporization of the prostate may cause higher complication rates compared to bipolar loop resection: a randomized prospective trial

Osama Abdelwahab¹ · Mohamed Habous² · Mohammed Aziz³ · Mohammed Sultan³ · Mohammed Farag⁴ · Richard Santucci⁵ · Saleh Binsaleh⁶ 

Received: 2 August 2019 / Accepted: 9 September 2019 / Published online: 14 September 2019
© Springer Nature B.V. 2019

Abstract

Introduction Transurethral resection of the prostate (TURP) by resection loop or vaporization button is becoming a standard of care due to its better safety profile (less bleeding and less incidence of TUR syndrome). However, there are published data showing bipolar vaporization may be associated with increased late complications. In this study, we compared results of bipolar TURP using the resection loop versus vaporization button for treatment of benign prostatic hyperplasia (BPH) to determine the relative safety profile.

Patients and methods Between January 2013 and March 2014, 89 patients with BPH were randomized to surgical intervention either by Olympus (Gyrus) Bipolar loop TURP or Olympus (Gyrus) Bipolar button vaporization. Inclusion criteria were; BPH with Q-max < 10 ml/s, IPSS > 18 and prostate volume > 40 g. All patients were evaluated preoperatively and at 1, 3 and 9 months. Evaluation included IPSS, uroflowmetry, prostate volume by ultrasound. Clavien complications and operative time were recorded. Statistical analysis was done using Statistical Package of Social Science (SPSS) version 17 software.

Results 44 patients were included in bipolar TURP and 45 patients in vaporization arm. Preoperative mean prostate volume (59 g versus 58 g, $p=0.52$) and mean IPSS (19 versus 20, $p=0.38$) were equivalent in both groups. Vaporization was associated with a significant increase in operative time (mean of 81 ± 15 min range 40–110 versus 55 ± 10 min range 30–70 min, $p < 0.001$), less blood loss (0.8% versus 2.0% drop in hemoglobin, $p < 0.001$) but increased postoperative urinary frequency (80% versus 50%, $p < 0.001$), hematuria with clots up to 4 weeks post surgery (20% versus 2%, $p < 0.001$) and postoperative urethral stricture (11% versus 0%, $p < 0.001$). Both techniques improved urine flow with Q-max (17 ml/s versus 18 ml/s $p=0.22$). Prostate volume (32 g versus 31 g, $p=0.31$) and IPSS (6 versus 5, $p=0.22$), were comparable in both treatment arms.

Conclusions Bipolar vaporization of the prostate, despite being a technically robust, speedy and with less intraoperative bleeding, appears to be associated with increased postoperative irritative symptoms, increased late-onset postoperative bleeding and high urethral stricture rates.

Keywords Bipolar vaporization · Prostate · Bipolar loop resection · Prospective trial

✉ Saleh Binsaleh
binsaleh@ksu.edu.sa

¹ Urology Department, Benha University, Benha, Egypt

² Urology and Andrology Department, Elaj Medical Centers, Jeddah, Saudi Arabia

³ Urology Department, Menoufia University, Al Minufya, Egypt

⁴ Urology Department, Al-Azhar Faculty of Medicine, Assiut, Egypt

⁵ Detroit Medical Center, Michigan State University, Detroit, USA

⁶ Division of Urology, Department of Surgery, Faculty of Medicine, King Saud University, PO Box 36175, Riyadh 11419, Saudi Arabia

Introduction

Benign prostatic enlargement (BPE) is a progressive disease affecting older males and represents a common problem for aging men [1]. It can lead to lower urinary tract symptoms (LUTS) and affects quality of life [2]. Although monopolar transurethral resection of the prostate (TURP) is considered the endoscopic gold standard for the surgical removal of symptomatic BPE, newer technologies including bipolar resection and bipolar electro-vaporization techniques are increasingly used [3–10]. These bipolar TURP procedures have similar or superior performance characteristics to monopolar TURP [10–13] and adding the benefits of fewer perioperative complications (less blood loss, earlier removal of the catheter and saline irrigation allows more time for removal of large adenoma with negligible risk of TUR syndrome) [14–20].

Bipolar transurethral resection of prostate technology uses high frequency energy to create a vapor layer of plasma which contains energy-charged particles that induce tissue disintegration through molecular dissociation. As the active and return electrodes are placed on the same axis of the resectoscope, high current densities are achieved locally and distant negative effects reduced [21]. This technology provides an advantage over the monopolar system in which the energy current passes through the patient's body, from the active electrode, placed on the resectoscope, toward the return plate placed on the patient's leg, with several disadvantages such as heating of deeper tissue, nerve or muscle stimulation, and possible malfunction of the cardiac pacemaker [22].

Although these are commonly performed procedures, there is little data reporting the relative performance characteristics of bipolar loop resection compared to bipolar vaporization. While bipolar vaporization seems to be slightly less speedy than bipolar resection, vaporization technique is associated with almost no intraoperative bleeding. We endeavored to compare these two approaches, hypothesizing that they would have equivalent performance characteristics.

Patients and methods

This prospective randomized study was done between January 2013 and March 2014, patients with moderate to severe LUTS due to BPE were included in this study. Simple randomization was used to divide patients into two groups (simple randomization, one case vaporization and one patient resection consecutively). Group 1 included patients who underwent bipolar TURP using Olympus Gyrus Bipolar Loop and Group 2 included patients who

underwent bipolar plasma vaporization using Olympus Gyrus Button Vaporization system. Inclusion criteria were: BPH with Q-max < 10 ml/s, IPSS > 18 and prostate volume > 40 g. Exclusion criteria were active urinary tract infection, coagulopathy, neurogenic bladder, prostate volume above 80 g, PSA above 4 ng/ml or abnormal DRE, previous urethral stricture or urethral surgery, presence of bladder stones or renal impairment. All patients were evaluated preoperatively by history, IPSS and quality of life (QoL) questionnaire, physical examination, laboratory investigations, uroflowmetry test with residual urine (RU), transrectal ultrasound (TRUS) and pelvi-abdominal ultrasound. All patients were followed up at 1, 3, and 9 months postoperatively by IPSS, uroflowmetry and TRUS. Operative time was recorded. All complications in perioperative period were recorded and classified according to modified Clavien system [23].

Informed written consent was taken from all participants and study protocol was approved from Local ethical committee. All procedures were performed by single surgeon under spinal anesthesia. Surgical protocol starts with urethral dilation up to size 26 French before insertion of the resectoscope. 24 French resectoscope was used in both groups. The procedure was performed via continuous irrigation system using normal saline. The Olympus bipolar generator was set to coagulation at 150 W and cutting at 270 W, doing the standard technique of bipolar resection and vaporization in both groups. At the end of the procedure triple way Foley's catheter, 20 French was placed for 24–48 h postoperatively in all patients, and irrigation with saline was continued till urine became clear. Data were collected, tabulated and statistically analyzed using Statistical Package of Social Science (SPSS) version 17 software. Suitable statistical techniques were computed (frequencies, mean, standard deviation and range).

Results

The study included 44 patients in bipolar TURP group, and 45 in bipolar vaporization group (Table 1). No patient has history of urine retention requiring indwelling

Table 1 Pre-operative variables

Variables (mean ± standard deviation)	Loop resection (Group I)	Vaporization (Group II)	<i>p</i> value
Number of patients	44	45	NA
Age (years)	52.2 ± 11.9	51.7 ± 11.2	0.3
Q-max pre-op (ml/s)	8.1 ± 7.7	9.01 ± 4.1	0.22
Prostate volume (g)	58.2 ± 12.5	59.4 ± 13.9	0.52
IPSS	19.9 ± 1.4	19.1 ± 1.2	0.38

catheterization preoperatively. There was no significant age difference in both groups [mean age in group-1 (52.2) and in group-2 (51.7), $p = 0.25$]. Preoperative prostate volume was similar in both groups (59 g versus 58 g, $p = 0.52$), and similarly IPSS showed insignificant difference (19 versus 20, $p = 0.38$). Vaporization was associated with significant increase in operative time [81.4 ± 15.3 min, range (40–110), versus 55.5 ± 9.8 min, range (30–70), $p < 0.001$], less blood loss (0.8% compared to 2% drop in hemoglobin, $p < 0.001$) but increased post-operative urinary frequency (80% versus 50%, $p < 0.001$), hematuria with clots as long as 4 weeks after surgery (20% versus 2%, $p < 0.001$) and postoperative urethral stricture (11% versus 0%, $p = < 0.001$) (Table 1). Postoperatively both techniques improved Q-max (17 ml/s versus 18 ml/s, $p = 0.22$), postoperative prostate volume measured by TRUS (32 g versus 31 g, $p = 0.31$) and IPSS (6 versus 5, $p = 0.22$) equivalently. There was no significant difference between the two groups regarding improvement in postoperative IPSS, Q-max and prostate volume. Postoperative irritative symptoms (frequency, urgency, and nocturia) were more in vaporization group and improved gradually with time (80%, 47%, 29%) at 1, 3, and 9 months, respectively (Clavien1). After 6 months postoperatively, five patients (11%) developed urethral stricture and all were in

the vaporization group (three were at bulbomembranous urethra and two at glandular urethra-Clavien3a) (Table 2).

There was no significant difference regarding hospital stay (1.3 days versus 1.8 days, $p = 0.25$) or catheterization period (1.5 days versus 1.9 days, $p = 0.22$).

Discussion

The treatment of LUTS due to infravesical obstruction secondary to BPE is constantly evolving. Therapeutic modalities for moderate and severe conditions begin with pharmacological treatment and may progress to minimally invasive, laparoscopic, robot-assisted or open surgical alternative.

Until recently, monopolar transurethral resection of the prostate (TURP) was considered a gold standard for the treatment of prostates with a volume lower than 80 cm³ due to its effectiveness and low cost. However, this established technique is associated with some relevant complications, such as urethral stenosis, bleeding, bladder neck sclerosis and especially post-TURP syndrome, due to the need for hypotonic infusion fluid to avoid electrical conduction. Post-TURP syndrome consists of water intoxication alongside hyponatremia, and can lead to the occurrence of cerebral edema.

Table 2 Intra and postoperative variables

Variables (mean \pm standard deviation)	Loop resection (Group I)	Vaporization (Group II)	<i>p</i> value
Operative time (min)	55.5 \pm 9.8	81.4 \pm 15.3	< 0.001
Postoperative Hg (% drop)	1.96 \pm 0.2	0.8 \pm 0.4	< 0.001
Q-max post-op (ml/s)			
1 month post-op	18.1 \pm 7.2	17.2 \pm 6.1	0.22
3 month post-op	18.7 \pm 9.3	17.9 \pm 1.1	0.52
9 month post-op	19.1 \pm 1.3	18.3 \pm 2.1	0.39
Prostate volume (g)	30.6 \pm 6.3	31.8 \pm 5.1	0.23
IPSS			
1 month post-op	7.8 \pm 1.1	7.9 \pm 1.3	0.22
3 month post-op	6.8 \pm 1.7	6.9 \pm 1.4	0.24
9 month post-op	5.2 \pm 1.3	6.9 \pm 1.1	0.25
Post-operative morbidity (frequency, urgency, nocturia)			
1 month	22 (50%)	36 (80%)	< 0.001
3 month	10 (23%)	21 (47%)	
9 month	1 (2%)	13 (29%)	
Hematuria with clots			
2 weeks	1 (2%)	2 (4%)	< 0.001
3 weeks	0	3 (7%)	
4 weeks	0	4 (9%)	
Stricture urethra			
6 month	0	5 (11%)	< 0.001

Bold values indicate statistical significance

The incorporation of bipolar technology represents a significant evolution in the TURP technique in recent years. Bipolar TURP presents a considerable advantage given the fact that it can be performed with normal saline solution, with excellent results in relation to a greater volume of resection within the same surgical time.

The search for new therapeutic modalities for any disorder is necessary and natural, even more so in times of rapid technological evolution. This is no different in the treatment of BPH, and new options are already beginning to be established in clinical practice in accordance with the consolidation and scientific support for such. Recently laser and electro-vaporization techniques are widely adopted [3]. In particular, bipolar Transurethral vaporization of the prostate (TUVP) provides better hemostasis [24], and the use of isotonic irrigation fluid permits better intraoperative visualization and treatment of patient with increased risk of bleeding [24]. This technique is gaining popularity as it is easy to do, easy to learn, and associated virtually with no or very minimal bleeding risk [25]. Additionally, bipolar TURP is proven a safe and highly effective treatment modality for BPE even in the elderly patients with prostate glands over 100 g. Its clinical efficacy and postoperative 12th month's results were similar to open suprapubic simple prostatectomy [26].

In our current study, we randomly compared bipolar loop TURP and bipolar vaporization in two comparable groups of patients with BPE.

Our data showed that while bipolar vaporization of the prostate was associated with equivalent efficacy and less bleeding, this benefit came at a significant cost. In our study, operative times were significantly (67%) longer for bipolar vaporization compared to bipolar loop resection. This fact has been reported by others, and is consistent with the assertion that vaporization achieves vaporization rates of no more than 1 min/1 cc of prostatic tissue [19]. Ho et al. also reported longer mean operative time for plasma kinetic vaporization compared with standard TURP (32.6 min versus 28.5 min) [12]. However, others have reported a similar operating time compared to TURP techniques. Dunsmuir et al. showed that bipolar electro-vaporization and TURP had similar operation time (33 versus 26 min, $p=0.78$) [27]. Geavlete et al. actually had shorter operating time (39.7 min) with bipolar vaporization over bipolar TURP (52.1 min) and monopolar TURP (55.6 min) ($p=0.0001$) [19]. This was also confirmed by Falahatkar et al. [28].

In our study there was no significant difference in both groups between hospital stay or catheterization period (1.3, 1.8 and 1.5, 1.9) for group 1 and 2, respectively. These results are in accordance with previous publications [4, 29, 30].

We and other published studies have found significant improvement in IPSS and Q-max along various follow-up

durations for vaporization and vaporization-resection (including bipolar technology) [4, 6, 19, 30–32]. In Geavlete et al. [19] trial, bipolar vaporization actually had significantly better voiding results compared to bipolar or monopolar TURP.

There was significantly less bleeding in our vaporization group compared to bipolar loop TURP (hematocrit drops of 0.8% versus 1.9%, respectively, $p=0.0001$) but this was not clinically significant as all but one patient in vaporization group manifested hemodynamic instability or required blood transfusion.

The mean hemoglobin drop after bipolar vaporization (0.5 g/dL) was significantly lower than bipolar TURP (1.2 g/dL) and monopolar TURP (1.6 g/dL) in Geavlete et al. [19]. Ho et al. [12] also reported bipolar plasma kinetic vaporization had significantly lower hemoglobin drop (0.8 g/dL) compared with standard monopolar TURP (1.4 g/dL).

The presence of significant number of delayed postoperative hematuria after bipolar vaporization was a surprising and concerning finding in our series. Significant postoperative bleeding occurred in only one patient (2%) 2 weeks after bipolar loop TURP, and was managed conservatively (Clavien 1). In the bipolar vaporization group, bleeding occurred in 9 patients (20%): 2 after 2 weeks, 3 after 3 weeks and in 4 patients after 4 weeks, all managed conservatively (Clavien 1) except one patient who developed clot retention and significant hematuria requiring cystoscopic management and blood transfusion due to significant hemoglobin drop (Clavien3b). Other studies also reported bleeding after bipolar vaporization, but at levels similar to bipolar loop TURP. Ahyai et al. found no significant difference in perioperative complication rates in TUVP (14%) and bipolar loop TURP (12%) as well as in the intraoperative or late complications [33]. Similarly, no significant difference between bipolar TUVP and bipolar loop TURP in the complications rate was observed according to modified Clavien classification of complications (10% versus 12%), respectively. These reported complications included gross hematuria requiring re-catheterization, blood transfusion, transient incontinence, frequency and nocturia. [28, 32].

In addition to a higher incidence of delayed bleeding, there were more storage symptoms in the early postoperative period surfaced with bipolar vaporization, which had previously been a common general impression of practitioners worldwide.

Urethral stricture occurred in 5 cases (11%) of group 2 and discovered after 6 months of postoperative follow-up period. All patients had annular strictures and managed by urethral dilation. The bipolar TURP system with its passive electrode located on the sheath of the resectoscope has consistently raised speculation about the electrical current leakage, which potentially can cause urethral stricture. In addition, urethral stricture

formation appears to be associated with longer operative time, which is the case in our vaporization group. This could be due to prolonged ischemia of urethra from contact with resectoscope sheath. The returning current flow, which can induce heat in the resectoscope sheath, could be another factor. These possibilities should be confirmed with further studies. In the study by Komura et al., the incidence of postoperative urethral stricture after the “quasi-bipolar” TURIS system appeared to be significantly higher in the TURIS group and was more commonly located in the membranous urethra [34]. The authors believed that the mechanism of urethral stricture after TURIS was different from what is described for bladder neck contracture after monopolar TURP. They suggested that different mechanism of current flow in the TURIS system might cause some electrophysiological stress to the membranous urethra, a point where the returning current interacts with the urethral tissue and the passive electrode sheath. No patient developed bladder neck contracture in our study in either of the treatment arms. In the same study by Komura et al., it was observed that the higher urethral stricture rate in the TURIS group was significantly associated with longer operation time and larger preoperative prostate volume of > 70 ml. Tan et al., reported urethral stricture rate of about 3.5% after bipolar Gyrus Plasma Kinetic Tissue Management System (PK-TURP) and postulated that this risk factor is intimately associated with the returning current flow of the PK-TURP system to cause Urethral Stricture [35]. Similarly, Kumar et al. reported urethral stricture rate of about 7.5% after TURIS method [36]. On the other hand, TURP by whatever modality invariably leads to mechanical and thermal stress. Besides longer operative time and longer catheter time, the other factors that cause mechanical stress are an oversized resectoscope and its inappropriate axial and rotating movements [37]. In our study, the fact that a larger resectoscope size might be responsible for urethral stricture was nullified using a 24 Fr resectoscope for both the treatment arms.

Although this study presents new data comparing bipolar vaporization to loop resection TURP in prospective cohort, our study is not without limitations. The limited sample size and the relatively short follow-up period make it difficult to ascertain long-term efficacy, and late failures. In addition, our patients as part of informed consent were informed as to the type of surgery they had, and this factor may have influenced their subjective reporting afterwards post operatively. Further studies of longer duration and larger sample size are required to compare the efficacy and cost-effectiveness of vaporization technique with the standard loop resection of prostate.

Conclusions

Bipolar vaporization of the prostate, despite being a technically robust, speedy procedure with less intraoperative bleeding, it appears to be associated with increased postoperative irritative symptoms, greatly increased delayed postoperative bleeding, and noticeable high urethral stricture rates.

Compliance with ethical standards

Conflict of interest All authors declare that there are no competing financial interests.

Ethical approval All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants included in this study.

References

1. Strope SA et al (2012) Population based comparative effectiveness of transurethral resection of the prostate and laser therapy for benign prostatic hyperplasia. *J Urol* 187(4):1341–1345
2. Zhang X et al (2012) Photoselective vaporization versus transurethral resection of the prostate for benign prostatic hyperplasia: a meta-analysis. *J Endourol* 26(9):1109–1117
3. Bucuras V, Bardan R (2011) Bipolar vaporization of the prostate: is it ready for the primetime? *Ther Adv Urol* 3(6):257–261
4. Reich O et al (2010) Plasma vaporisation of the prostate: initial clinical results. *Eur Urol* 57(4):693–697
5. Michielsen DP et al (2007) Bipolar transurethral resection in saline—an alternative surgical treatment for bladder outlet obstruction? *J Urol* 178(5):2035–2039 (**discussion 2039**)
6. Tefekli A et al (2005) A hybrid technique using bipolar energy in transurethral prostate surgery: a prospective, randomized comparison. *J Urol* 174(4 Pt 1):1339–1343
7. Reich O (2009) Bipolar transurethral resection of the prostate: what did we learn, and where do we go from here? *Eur Urol* 56(5):796–797
8. Wendt-Nordahl G et al (2004) The Vista system: a new bipolar resection device for endourological procedures: comparison with conventional resectoscope. *Eur Urol* 46(5):586–590
9. Djavan B et al (2010) Durability and retreatment rates of minimal invasive treatments of benign prostatic hyperplasia: a cross-analysis of the literature. *Can J Urol* 17(4):5249–5254
10. Van Hest P, D’Ancona F (2009) Update in minimal invasive therapy in benign prostatic hyperplasia. *Minerva Urol Nefrol* 61(3):257–268
11. Fagerstrom T, Nyman CR, Hahn RG (2011) Complications and clinical outcome 18 months after bipolar and monopolar transurethral resection of the prostate. *J Endourol* 25(6):1043–1049
12. Ho HS et al (2007) A prospective randomized study comparing monopolar and bipolar transurethral resection of prostate

- using transurethral resection in saline (TURIS) system. *Eur Urol* 52(2):517–522
13. Mamoulakis C, Ubbink DT, de la Rosette JJ (2009) Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. *Eur Urol* 56(5):798–809
 14. Ho HS, Cheng CW (2008) Bipolar transurethral resection of prostate: a new reference standard? *Curr Opin Urol* 18(1):50–55
 15. Fagerstrom T, Nyman CR, Hahn RG (2010) Bipolar transurethral resection of the prostate causes less bleeding than the monopolar technique: a single-centre randomized trial of 202 patients. *BJU Int* 105(11):1560–1564
 16. Yoon CJ et al (2006) Transurethral resection of the prostate with a bipolar tissue management system compared to conventional monopolar resectoscope: one-year outcome. *Yonsei Med J* 47(5):715–720
 17. Kwon JS et al (2011) Comparison of effectiveness of monopolar and bipolar transurethral resection of the prostate and open prostatectomy in large benign prostatic hyperplasia. *Korean J Urol* 52(4):269–273
 18. McClelland M Jr (2011) Olympus PlasmaButton transurethral vaporization technique for benign prostatic hyperplasia. *Can J Urol* 18(2):5630–5633
 19. Geavlete B et al (2011) Bipolar plasma vaporization vs monopolar and bipolar TURP-A prospective, randomized, long-term comparison. *Urology* 78(4):930–935
 20. Reich O, Gratzke C, Stief CG (2006) Techniques and long-term results of surgical procedures for BPH. *Eur Urol* 49(6):970–978 (**discussion 978**)
 21. Wendt-Nordahl G, Häcker A, Reich O, Djavan B, Alken P, Michel MS (2004) The Vista system: a new bipolar resection device for endourological procedures: comparison with conventional resectoscope. *Eur Urol* 46(5):586–590
 22. Kellow NH (1993) Pacemaker failure during transurethral resection of the prostate. *Anaesthesia* 48(2):136–138
 23. Mamoulakis C et al (2011) The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostate. *World J Urol* 29(2):205–210
 24. El-Shaer W, Abou-Taleb A, Kandeel W (2017) Transurethral bipolar plasmakinetic vapo-enucleation of the prostate: is it safe for patients on chronic oral anticoagulants and/or platelet aggregation inhibitors? *Arab J Urol* 15(4):347–354
 25. Elsakka AM et al (2016) A prospective randomised controlled study comparing bipolar plasma vaporisation of the prostate to monopolar transurethral resection of the prostate. *Arab J Urol* 14(4):280–286
 26. Coskuner ER, Ozkan TA, Koprulu S, Dillioglugil O, Cevik I (2014) The role of the bipolar plasmakinetic TURP over 100 g prostate in the elderly patients. *Int Urol Nephrol* 46(11):2071–2077
 27. Dunsmuir WD et al (2003) Gyrus bipolar electrovaporization vs transurethral resection of the prostate: a randomized prospective single-blind trial with 1 y follow-up. *Prostate Cancer Prostatic Dis* 6(2):182–186
 28. Falahatkar S et al (2014) Bipolar transurethral vaporization: a superior procedure in benign prostatic hyperplasia: a prospective randomized comparison with bipolar TURP. *Int Braz J Urol* 40(3):346–355
 29. Botto H et al (2001) Electro vaporization of the prostate with the Gyrus device. *J Endourol* 15(3):313–316
 30. Dincel C et al (2004) Plasma kinetic vaporization of the prostate: clinical evaluation of a new technique. *J Endourol* 18(3):293–298
 31. Otsuki H et al (2012) Transurethral resection in saline vaporization: evaluation of clinical efficacy and prostate volume. *Urology* 79(3):665–669
 32. Rassweiler J et al (2007) Bipolar transurethral resection of the prostate—technical modifications and early clinical experience. *Minim Invasive Ther Allied Technol* 16(1):11–21
 33. Ahyai SA et al (2010) Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. *Eur Urol* 58(3):384–397
 34. Komura K, Inamoto T, Takai T, Uchimoto T, Saito K, Tanda N, Minami K, Uehara H, Takahara K, Hirano H, Nomi H, Kiyama S, Watsuji T, Azuma H (2014) Could transurethral resection of the prostate using the TURis system take over conventional monopolar transurethral resection of the prostate? A randomized controlled trial and midterm results. *Urology* 84(2):405–411
 35. Tan GH, Shah SA, Ali NM, Goh EH, Singam P, Ho CCK, Zainuddin ZM (2017) Urethral strictures after bipolar transurethral resection of prostate may be linked to slow resection rate. *Investig Clin Urol* 58(3):186–191
 36. Kumar BN, Srivastava A, Sinha T (2019) Urethral stricture after bipolar transurethral resection of prostate—truth vs hype: a randomized controlled trial. *Indian J Urol* 35(1):41–47
 37. Faul P, Fastenmeier K (2008) The role of lubrication in transurethral electrical resection. *Urologe A* 47(3):326–330

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com